GlassScriptPhysician profile
Harsha Vyas
NPI 1447447933
$24,201.50
in general payments reported to CMS, 2019-2025
75 companies · $2,446 in 2025
The $2,446 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,147 · 2020: $4,059 · 2021: $4,587 · 2022: $3,380 · 2023: $4,581 · 2024: $2,001 · 2025: $2,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,190 · Consulting Fee: $1,405 · Education: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,189.89 |
| Consulting Fee | $1,405.00 |
| Education | $433.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,301.53 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $1,781.45 | 2019-2023 | Opdivo, Pomalyst |
| Novartis Pharmaceuticals Corporation | $1,723.77 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,152.07 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Mirati Therapeutics, INC. | $949.21 | 2023-2024 | Krazati |
| Genentech USA, INC. | $940.13 | 2019-2025 | Polivy, Lunsumio, Gazyva |
| Janssen Biotech, INC. | $873.79 | 2019-2025 | Erleada, Darzalex, Tecvayli |
| Athenex Pharmaceutical Division, LLC | $867.39 | 2019 | |
| Asd Specialty Healthcare, LLC | $852.00 | 2019-2025 | |
| Daiichi Sankyo INC. | $824.59 | 2019-2025 | Injectafer, Enhertu, Datroway |
| Pfizer INC. | $797.86 | 2019-2025 | |
| Amgen INC. | $712.55 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Seagen INC. | $653.71 | 2020-2025 | Tivdak, Tukysa, Adcetris |
| Incyte Corporation | $543.83 | 2019-2025 | Jakafi, Monjuvi, Jakafi |
| Celgene Corporation | $523.72 | 2019-2024 | Reblozyl, Pomalyst, Opdualag |
Show all 74 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsha Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.